Would you consider patritumab deruxtecan on clinical trial instead of chemotherapy for patients with EGFR+ lung cancer progressive on osimertinib?  

Patritumab deruxtecan has shown promising activity in patients with sensitizing EGFR mutations who have had disease progression on osimertinib or other TKI. A phase 1 trial was recently published showing a response rate of 39% in patients who had progressed on prior TKI and a median progression-free...

After progression on EGFR-TKIs, salvage therapy in EGFR-mutant NSCLC has limited benefit due to diverse and heterogeneous resistance mechanisms. Osimertinib resistance can be due to on-target resistance, due to upregulation of bypass signaling pathways, or due to histologic transformations. (Piper-V...